{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.29","value":"-5.7"},{"groupId":"OG001","spread":"20.74","value":"-4.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"138"}],"units":"Participants"}],"description":"The Global Health Status Score is derived from question 29 and 30 on the EORTC-QLQ-C30 tool. The change in score was assessed between baseline and week 12 in patients treated with advanced GIST treated with avapritinib compared to patients treated with regorafenib. The Global Health Status Score score range is 0 to 100 with a higher score indicating better global health status. A positive change indicates improvement in global health status.","dispersionType":"Standard Deviation","groups":[{"description":"300 mg PO QD avapritinib: Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.","id":"OG000","title":"Avapritinib"},{"description":"160 mg PO QD regorafenib: Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).","id":"OG001","title":"Regorafinib"}],"paramType":"MEAN","populationDescription":"Intent-to-Treat Population with both a baseline and a Week 12 measurements.","reportingStatus":"POSTED","timeFrame":"Difference between baseline and week 12 of treatment","title":"European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30). Change in Individual Scores in Patients With Advanced GIST Treated With Avapritinib Compared to Patients Treated With Regorafenib","type":"SECONDARY","unitOfMeasure":"scores on a scale"}